Skip to main content
Find more clinical trials

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)

Start: October 2016
End: July 2022
Enrollment: 2000

What Is This Study About?

The ADNI3 study is the third in a series of trials since 2004 to identify markers for diagnosis and tracking the progression of Alzheimer's disease. Diagnostic, clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three groups of participants: cognitively normal, MCI, and mild Alzheimer's dementia. Investigators will evaluate changes in participants' cognition (including memory, reasoning, and language). Participants will undergo clinical, cognitive, and genetic tests, as well as positron emission tomography (PET) and magnetic resonance imaging (MRI) brain scans and cerebrospinal fluid collection for up to five years.

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: 90 Years

Must have:

All New Participants

  • Good general health
  • Study partner who has frequent contact with participant (minimum average of 10 hours per week) and can accompany participant to clinic visits
  • Modified Hachinski Ischemic Score of less than or equal to 4; Geriatric Depression Scale score of less than 6
  • Completion of six grades of education or good work history
  • Willing to undergo repeated MRIs, at least two PET scans, blood collection, and at least one lumbar puncture
  • Willing to share genetic data and biomarker samples
  • Fluent in English or Spanish

Cognitively Normal Participants

  • Cognitively normal, based on absence of significant impairment in cognitive function or activities of daily living (currently recruiting non-Caucasian participants only for the normal cognition group)
  • With or without subjective memory complaints
  • Normal memory function score; Mini-Mental State Examination (MMSE) score of 24-30 (exceptions considered for less than 8 years of education); Clinical Dementia Rating of 0; Memory Box score of 0

Participants with MCI

  • Subjective memory concern reported by participant, study partner, or clinician
  • Abnormal memory function score; MMSE score of 24-30 (exceptions considered for less than 8 years of education); Clinical Dementia Rating of 0.5; Memory Box score of at least 0.5
  • General cognition and functional performance such that a diagnosis of Alzheimer's disease cannot be made by the site physician
  • Permitted medications if taking at least 4 weeks: stable dose of antidepressants lacking significant anticholinergic effects, cholinesterase inhibitors or memantine, estrogen replacement therapy, gingko biloba; must discontinue psychoactive medications at least four weeks before screening

Participants with Alzheimers Disease

  • Subjective memory concern reported by participant, study partner, or clinician
  • Abnormal memory function score; MMSE score of 20-24 (exceptions considered for less than 8 years of education); Clinical Dementia Rating of 0.5 or 1.0
  • Meets criteria for probable Alzheimers disease
  • Permitted medications if taking at least 4 weeks: same as for MCI above

Must NOT have:

  • Significant neurological disease other than Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurological deficits or known structural brain abnormalities
  • Screening/baseline MRI brain scan with evidence of infection, infarction or other focal lesions, or multiple lacunes or lacunes in a critical memory structure
  • Contraindications to MRI including pacemaker or metal fragments or foreign objects in the eyes, skin, or body
  • Major depression or bipolar disorder within the past year; psychotic features, agitation, or behavioral problems within the last three months; history of schizophrenia
  • Current treatment for obsessive-compulsive disorder or attention deficit disorder
  • Alcohol or substance abuse/dependence within the past two years
  • Any significant systemic illness or unstable medical condition that could lead to difficulty participating in the study
  • Pregnant, lactating, or of childbearing potential (women must be two years postmenopausal or surgically sterile)
  • Clinically significant abnormalities in B12 or thyroid function tests
  • Prohibited medications: psychoactive medications (certain antidepressants, neuroleptics, chronic anxiolytics, or sedative hypnotics); warfarin or other anticoagulants (such as dabigatran, rivaroxaban, and apixaban); investigational agents one month prior to entry and during the study
  • Residence in skilled nursing facility
  • Participation in clinical studies involving neuropsychological measures collected more than one time per year

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Who Is the General Study Contact?

To find out more information about the ADNI3 study, please visit www.ADNI3.org.

Study Contact
ADNI Central Contact

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Alabama
University of Alabama, Birmingham
Birmingham, AL 35294
Recruiting
Loren Brown Ashley
Arizona
Banner Alzheimer's Institute
Phoenix, AZ 85006
Recruiting
David Parkhurst
Barrow Neurological Institute
Phoenix, AZ 85013
Recruiting
Angelica Garcia
Banner Sun Health Research Institute
Sun City, AZ 85351
Recruiting
Kelly Clark
California
University of California, Irvine
Irvine, CA 92697
Recruiting
Beatriz Yañez
University of California, San Diego
La Jolla, CA 920371707
Recruiting
Mollie Paster
Long Beach VA Neuropsychiatric Research Program
Long Beach, CA 90822
Recruiting
Sakineh (Parvin) Khalaghizadeh
University of Southern California
Los Angeles, CA 900335310
Recruiting
Nadine Diaz
University of California, Los Angeles
Los Angeles, CA 90095
Recruiting
Celine Ossinalde
VA Palo Alto HSC / Stanford School of Medicine
Palo Alto, CA 94304
Recruiting
Joy Taylor
University of California, San Francisco
San Francisco, CA 94158
Recruiting
Elise Ong
University of California, Davis
Walnut Creek, CA 945985900
Recruiting
Hongzheng Zhang
Connecticut
Yale University School of Medicine
New Haven, CT 65103330
Recruiting
Emmie Banks
District of Columbia
Georgetown University
Washington, DC 200072145
Recruiting
Kelly McCann
Howard University
Washington, DC 200600001
Recruiting
Saba Wolday
Florida
Mayo Clinic, Jacksonville
Jacksonville, FL 32224
Recruiting
Sochenda Chea
Wien Center for Clinical Research
Miami Beach, FL 331402877
Recruiting
Maria Greig-Custo
University of South Florida - Health Byrd Alzheimer Institute
Tampa, FL 336134808
Recruiting
Juris Janavs
Georgia
Emory University
Atlanta, GA 30322
Recruiting
Rebecca Byram
Illinois
Northwestern University
Chicago, IL 606113010
Recruiting
Brittanie Muse
Rush University Medical Center
Chicago, IL 606123806
Recruiting
Erin Yurko
Indiana
Indiana University
Indianapolis, IN 46202
Recruiting
Christina Brown
Iowa
University of Iowa
Iowa City, IA 52242
Recruiting
Karen Ekstam-Smith
Kansas
University of Kansas
Fairway, KS 66205
Recruiting
Melissa Dodd
Kentucky
University of Kentucky
Lexington, KY 405042681
Recruiting
Dorothy Ross
Maryland
Johns Hopkins University
Baltimore, MD 212242764
Recruiting
Scott Rudow
Massachusetts
Brigham and Women's Hospital
Boston, MA 21155804
Recruiting
Nancy Coppelman
Boston University School of Medicine
Boston, MA 21182307
Recruiting
Jane Mwicigi
Michigan
University of Michigan, Ann Arbor
Ann Arbor, MI 481052967
Recruiting
Sara Raymo
Minnesota
Mayo Clinic, Rochester
Rochester, MN 559050001
Recruiting
Colleen Albers
Missouri
Washington University, St. Louis
Saint Louis, MO 631082215
Recruiting
David Winkfield
Nevada
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV 891060100
Recruiting
Heather Hudson
New York
Albany Medical College
Albany, NY 12208
Recruiting
Mary Eglow
Dent Neurologic Institute
Buffalo, NY 142261727
Recruiting
Michelle Rainka
New York University Medical Center
New York, NY 100166055
Recruiting
Karen Castro
Mount Sinai School of Medicine
New York, NY 100296552
Recruiting
Jonathan Greenberg
Columbia University
New York, NY 10032
Recruiting
Anton Kociolek
Nathan Kline Institute for Psychiatric Research
Orangeburg, NY 109621159
Recruiting
Antero Sarreal
University of Rochester
Rochester, NY 14620
Recruiting
Nancy Kowalski
North Carolina
Duke University Medical Center
Durham, NC 27710
Recruiting
Cammie Hellegers
Wake Forest University Health Sciences
Winston-Salem, NC 27157
Recruiting
Bevan Hoover
Ohio
Case Western Reserve University
Beachwood, OH 441224312
Recruiting
Parianne Fatica
Ohio State University
Columbus, OH 43210
Recruiting
Jennifer Icenhour
Oregon
Oregon Health & Science University
Portland, OR 972393011
Recruiting
Rachel Crissey
Pennsylvania
University of Pennsylvania
Philadelphia, PA 19104
Recruiting
Grace Stockbower
University of Pittsburgh
Pittsburgh, PA 15213
Recruiting
MaryAnn Oakley
Rhode Island
Rhode Island Hospital
Providence, RI 02903
Recruiting
Terry Fogerty
Butler Hospital Memory and Aging Program
Providence, RI 02906
Recruiting
Tara Tang
South Carolina
Roper St. Francis Hospital
Charleston, SC 29401
Recruiting
Allison Lapp
Tennessee
Vanderbilt University Medical Center
Nashville, TN 37212
Recruiting
Xuewen Gong
Texas
University of Texas, Southwestern MC at Dallas
Dallas, TX 75390
Recruiting
Amy Browning
Baylor College of Medicine
Houston, TX 77030
Recruiting
Nat Pacini
Houston Methodist
Houston, TX 77030
Recruiting
Jennifer Garrett
Wisconsin
University of Wisconsin
Madison, WI 537920001
Recruiting
Sandra Harding

Who Sponsors This Study?

Lead: University of Southern California

Collaborator Sponsor

  • Northern California Institute of Research and Education
  • National Institute on Aging (NIA)
  • Alzheimer's Therapeutic Research Institute

Source: ClinicalTrials.gov ID: NCT02854033